A new experimental drug, Nerandomilast, has shown potential in reducing lung inflammation and fibrosis in preclinical models of Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease ...
Restoring the gut microbiota through fecal microbiota transplantation reversed these effects. The treatment replenished CX3CR1-positive NK cells, reduced lung damage, and improved survival. Targeted ...
Sepsis and severe pneumonia are frequently accompanied by disruption of the gut microbiota, leading to immune dysfunction and ...
PI3K/AKT/mTOR pathway blockade with pan-PI3K/mTORC1/2 inhibition produced substantial PFS gains in PIK3CA wild-type disease, addressing an unmet need after CDK4/6 plus endocrine resistance. Adding ...
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small ...
FAYETTEVILLE, GA, UNITED STATES, March 10, 2026 /EINPresswire.com/ -- Chronic diabetic wounds fail to heal because ...
Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...
Can-Fite BioPharma ( (CANF) ) just unveiled an update.
Detailed price information for Sensei Biotherapeutics Inc (SNSE-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results